TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02534493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carpal Tunnel Tissue Manipulation Device (CTMD)
Description: This piece of rigid, shaped, biocompatible plastic (polypropylene) rated for skin contact and a strong but safe hypoallergenic biocompatible medical adhesive which bonds the skin over the carpal tunnel to the plastic piece for a duration of 2-14 hours.
Study: NCT04318561

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gallium-68 NODAGA-LM3 PET/CT
Description: Twenty patients will take this intervention. They will be further divided into two sub-groups with the same interventional radiopharmaceutical (Gallium-68 NODAGA-LM3) but different scanning protocols (Protocol A and Protocol B). The first enrolled 8 patients will go with Protocol A, who will undergo serial whole-body PET/CT scans at multiple time points (5m, 10m, 20m, 40m, 1h, 2h) after administering 40ug/150-200MBq Gallium-68 NODAGA-LM3. Baseline safety assessment will be conducted right before the study. The following 12 patients will go with Protocol B, who will undergo a whole-body PET/CT scan at 1 hour after administering 40ug/150-200MBq Gallium-68 NODAGA-LM3.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gallium-68 DOTA-LM3 PET/CT
Description: Twenty patients will take this intervention. They will be further divided into two sub-groups with the same intervention radiopharmaceutical (Gallium-68 DOTA-LM3) but different scanning protocols (Protocol C and Protocol D). The first enrolled 8 patients will go with Protocol C, who will undergo serial whole-body PET/CT scans at multiple time points (5m, 10m, 20m, 40m, 1h, 2h) after administering 40ug/150-200MBq Gallium-68 DOTA-LM3. Baseline safety assessment will be conducted right before the study. The following 12 patients will go with Protocol D, who will undergo a whole-body PET/CT scan at 1 hour after administering 40ug/150-200MBq Gallium-68 DOTA-LM3.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gallium-68 DOTATATE PET/CT
Description: All patients have to do a Gallium-68 DOTATATE PET/CT scan (40ug/150-200MBq, 1h post-injection) for comparison on the next day of LM3 scan. Safety assessment and tolerability of the previous LM3 study will be conducted right before the study.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gallium-68 DOTATATE PET/CT
Description: All patients have to do a Gallium-68 DOTATATE PET/CT scan (40ug/150-200MBq, 1h post-injection) for comparison on the next day of LM3 scan. Safety assessment and tolerability of the previous LM3 study will be conducted right before the study.
Study: NCT00057629

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual group therapy (TUGT)
Description: TUGT is delivered in ten weekly sessions, with 5 to 7 members and two counselors per group. There is not a formal, structured format for these groups; the counselors are sensitive to the participants' needs and follow their lead in terms of content covered in discussions and exercises. TUGT is conceptualized as supportive counseling and is based on the idea that members gain social support and information from one another.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive counseling (SC)
Description: Supportive counseling is an individual therapy delivered in 10 weekly, 90 minute sessions. During this treatment, the therapist helps the patient identify daily stresses that may or may not be related to traumatic events and discusses them in a supportive non-directive mode with a problem-solving orientation. The therapist uses active listening, encouragement of expression of feelings, praise, and encouragement. The goal of this present-focused treatment is to provide support and to help the client to identify problems and stresses of daily living and to help her cope with these. No instructions for exposure are given.
Study: NCT00613665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: helicobacter pylori vaccine
Description: Experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: helicobacter pylori vaccine
Description: Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: helicobacter pylori vaccine
Description: Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: helicobacter pylori vaccine
Description: Eight subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nine subjects, alum control (placebo comparator), 0,1,2,4 month schedule (served as control for arms 1-4), administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: helicobacter pylori vaccine
Description: Nine subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: helicobacter pylori vaccine
Description: Ten subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly
Study: NCT02849522

Intervention type: PROCEDURE
Intervention: Prostatic Artery Embolisation
Description: The aim of PAE for LUTS (due to BPH) is to reduce the blood supply of the prostate gland, causing some of it to undergo necrosis with subsequent shrinkage.~The procedure is usually performed with the patient under local anaesthetic and sedation. Using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation involves the introduction of microparticles to block these small prostatic arteries. Embolisation agents include polyvinyl alcohol (PVA), gelatine sponge and other synthetic biocompatible materials.~NICE published Interventional Procedures Guidance (IPG453) in April 2013. The evidence at the time of assessment was deemed inadequate in quantity and quality. Therefore, the procedure was given a 'Research-only' recommendation.

Intervention type: PROCEDURE
Intervention: TURP
Description: Transurethral resection of the prostate. A cystoscope is passed up the urethra to the prostate, where the surrounding prostate tissue is excised. This is a common operation for benign prostatic hyperplasia (BPH), with around 15,000 procedures performed in the UK per year (NHS Choices). The conventional TURP method of tissue removal utilizes a wire loop with electrical current flowing in one direction (monopolar) through the resectoscope to cut the tissue. Bipolar TURP allows saline irrigation and eliminates the need for an ESU grounding pad thus preventing TUR syndrome and reducing other complications.

Intervention type: PROCEDURE
Intervention: Open prostatectomy
Description: In an open prostatectomy the prostate is accessed through an incision that allows manual manipulation and open visualization through the incision. The most common types of open prostatectomy are retropubic prostatectomy (RP) or transvesical prostatectomy (TVP).

Intervention type: PROCEDURE
Intervention: Laser prostate surgery
Description: This surgical method (HoLEP or KTP/Greenlight) utilizes laser energy to remove tissue. With laser prostate surgery a laser fibre inserted via an endoscope is used to transmit laser energy to enucleate (HoLEP) or vaporise (KTP) the tissue. The specific advantages of utilizing laser energy rather than a traditional electrosurgical TURP is a decrease in the relative blood loss, elimination of the risk of TUR syndrome, the ability to treat larger glands, as well as treating patients who are actively being treated with anti-coagulation therapy for unrelated diagnoses.
Study: NCT03212989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HXTC
Description: Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.
Study: NCT01870908

Intervention type: DRUG
Intervention: tacrolimus

Intervention type: DRUG
Intervention: biological agents
Study: NCT00201227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: practice guideline adherence
Description: Project facilitator assist primary care practice clinicians and staff work in effective quality improvement teams through the use of facilitated collaborative meetings.
Study: NCT01659788

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 concomitant treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03888989

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Quadrivalent inactivated influenza vaccine (IIV)
Description: Quadrivalent inactivated influenza vaccine (IIV), Intramuscular Injection
Study: NCT02319759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: In the guselkumab group, Guselkumab 100 mg subcutaneous injection will be administered at Weeks 0, 4, 12, 20, 28, 36 and 44. In the placebo group, guselkumab 100 mg subcutaneous injection will be administered at Weeks 24, 28, 36 and 44 for participants remaining on placebo at Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: In the guselkumab group, Guselkumab 100 mg subcutaneous injection will be administered at Weeks 0, 4, 12, 20, 28, 36 and 44. In the placebo group, guselkumab 100 mg subcutaneous injection will be administered at Weeks 24, 28, 36 and 44 for participants remaining on placebo at Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: In both placebo and guselkumab groups, if the participants qualify for early escape, they will switch to receive ustekinumab 45 mg or 90 mg subcutaneous injection at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: In both placebo and guselkumab groups, if the participants qualify for early escape, they will switch to receive ustekinumab 45 mg or 90 mg subcutaneous injection at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In placebo group, Placebo subcutaneous injection will be administered at Weeks 0, 4, 12, and 20. In guselkumab group, placebo subcutaneous injection will be administered at Week 24 to maintain the blind.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In placebo group, Placebo subcutaneous injection will be administered at Weeks 0, 4, 12, and 20. In guselkumab group, placebo subcutaneous injection will be administered at Week 24 to maintain the blind.
Study: NCT04531644

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double stimulation
Description: the patients will be treated with two consecutive ovarian stimulations in one cycle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional ovarian stimulation
Description: the patients will be treated with one conventional ovarian stimulation in one cycle
Study: NCT01659853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47 gel 0.5%/CD07805/47 Vehicle
Description: To maintain masking, CD07805/47 gel 0.5% will be administered along with CD07805/47 gel vehicle.~During each treatment period (baseline to Day 15):~CD07805/47 gel 0.5%, topical, once daily and CD07805/47 gel vehicle, topical, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelaic acid gel 15%
Description: During each treatment period (baseline to Day 15): azelaic acid gel 15%, topical, twice daily
Study: NCT01611805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786
Description: Opaque Swedish orange body and cap.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786
Description: Opaque Swedish orange body and cap.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786
Description: Opaque Swedish orange body and cap.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786
Description: Opaque Swedish orange body and cap.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1605786 Placebo
Description: Opaque Swedish orange body and cap.
Study: NCT03421626

Intervention type: DEVICE
Intervention: Xpert BCR-ABL Ultra
Description: Semi-quantitation of BCR-ABL transcript in patients that have been previously diagnosed with CML
Study: NCT01085968

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PC based training
Description: Subjects sit at a computer and type a string of numbers that appears on the screen. As performance improves (# correct), the strings of numbers get longer. They are then instructed to repeat the string from memory. Performing these key entries from memory is a test of internally generated movement initiation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PC based training
Description: Subjects sit at a computer and type a string of numbers that appears on the screen. As performance improves (# correct), the strings of numbers get longer. They are then instructed to repeat the string from memory. Performing these key entries from memory is a test of internally generated movement initiation.
Study: NCT00628004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biatain Ibu
Description: Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Local best practice
Description: N/A - since intervention is local best practice
Study: NCT02907645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Local educational information
Description: Adult patients in this arm receive educational information regarding influenza vaccination based on local data

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: National educational information
Description: Adult patients in this arm receive educational information regarding influenza vaccination based on national data
Study: NCT00952120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GSUC
Description: Gauze-based wall suction negative pressure wound therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VAC
Description: Commercially available Wound VAC negative pressure wound therapy device (KCI, Inc.)
Study: NCT02438501

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose involved-field radiotherapy
Description: Low-dose involved-field RT (LD-IFRT) is given in 2 daily fractions (2×2 Gy). Involved-field of radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Involved-field radiotherapy
Description: Involved-field RT (IFRT) is given in 24 Gy in 12 fractions. Radiotherapy field defined by CALGB is encompassed the prechemotherapy gross tumor.
Study: NCT04541498

Intervention type: OTHER
Intervention: Impact of air pollution and climate changes
Description: To assess the short- and long- term impact of air pollution and climate changes

Intervention type: OTHER
Intervention: Impact of air pollution and climate changes
Description: To assess the short- and long- term impact of air pollution and climate changes
Study: NCT00767975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid , randomized, open label
Description: isoniazid 300mg/tab 1 tab qd, 6 months (the other treatment arm is rifampin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin, randomized, open label
Description: rifampin 300mg/capsule 2 caps qd, 4 months (the other treatment arm is isoniazid)
Study: NCT01767532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin 125 mg/5ml
Description: Reference product 20 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin 125 mg/5ml
Description: Reference product 20 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin 125 mg/5ml
Description: Test product 20 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin 125 mg/5ml
Description: Test product 20 ml
Study: NCT00424385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec + Sorafenib
Description: 400 mg Sorafenib every day (QD) 300mg Gleevec QD
Study: NCT01963923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation Program
Description: The pulmonary rehabilitation program includes an endurance training with a cycloergometer, a strength training with elastic bands and two dairy sessions of incentive spirometry with a volume-oriented device.
Study: NCT01498159

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist disease/medication management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist disease/medication management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-patient encounters

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-patient encounters

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist medication intensification and adherence support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist medication intensification and adherence support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist communication with primary care physicians

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist communication with primary care physicians

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist documentation in electronic medical record
Study: NCT01498159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist documentation in electronic medical record

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promoter-patient encounters in-person or by phone
Study: NCT00040443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX516

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01498159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promoter medication and lifestyle support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promoter communication with pharmacists
Study: NCT04109924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study: NCT03139669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viba collection brush
Description: HPV home collection kit using the viba collection brush to collect cervical cells for HPV DNA testing.
Study: NCT01621568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50mg/day for 4 weeks daily, by mouth with 2 weeks off (6 week cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50mg/day for 2 weeks daily, by mouth with 1 week off (3 week cycle)
Study: NCT05487222

Intervention type: DEVICE
Intervention: ICON
Description: hemodynamics variability in response to different fluid regiemens

Intervention type: DEVICE
Intervention: ICON
Description: hemodynamics variability in response to different fluid regiemens
Study: NCT02582112

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Active Comparator: Warming group
Description: Placebo Comparator: Control group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Warming group
Description: Placebo Comparator: Control group
Study: NCT02147899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYM-1219
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYM-1219
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT00254618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalamine
Description: oral tablet, 30 mg mesalamine/day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalamine
Description: oral tablet, 60 mg mesalamine/day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalamine
Description: oral tablet, 90 mg mesalamine/day for 28 days
Study: NCT01205152

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: asfotase alfa
Study: NCT00562055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-165442G; [S,S]-reboxetine
Study: NCT03814031

Intervention type: OTHER
Intervention: NO internvention
Description: NO internvention

Intervention type: OTHER
Intervention: NO internvention
Description: NO internvention
Study: NCT02213341

Intervention type: PROCEDURE
Intervention: Skin prick allergen test
Description: To test for hypersensitivity to milk, egg, or peanut

Intervention type: PROCEDURE
Intervention: Skin prick allergen test
Description: To test for hypersensitivity to milk, egg, or peanut

Intervention type: PROCEDURE
Intervention: Blood draw

Intervention type: PROCEDURE
Intervention: Blood draw